LexaGene Holdings Inc (CVE:LXG) (OTCMKTS:LXXGF) announced Wednesday that a major veterinary hospital in Massachusetts will house the first beta prototype of the company’s LX Analyzer.
The beta prototype identifies the presence of bacteria causing urinary tract infections in animals and screens samples for common antibiotic resistance factors so that veterinarians have the correct information to select the best course of treatment.
LexaGene's shares jumped 9.5% at C$0.69 in Toronto on Wednesday morning and 15.3% at US$0.52 on OTC markets.
Massachusetts-based LexaGene said the prototype had been placed at Massachusetts Veterinary Referral Hospital, which is among 24 hospitals owned by Ethos Veterinary Health, a US network of veterinary hospitals providing specialty and emergency care for pets.
“This placement marks a very significant milestone for the company and for the diagnostics industry,” said Dr Jack Regan, LexaGene’s founder and CEO.
According to Regan, the company selected Mass Vet to be its first site due to their reputation for being pioneers and thought leaders in veterinary medicine. “The doctors at Mass Vet are eager to test our cutting-edge technology to provide the best possible treatment for their patients,” he said.
LexaGene said it will continue placing devices at various other sites throughout the US as part of an ongoing beta test program.
“This will enable potential customers to experience the technology in their own facility so that they can compare LX-generated results to their standard testing methods,” Regan said in a statement. “We are confident these users will quickly appreciate the benefits of our technology and this will help seed future sales.”
LexaGene is pioneering the first fully automated pathogen detection platform for use in diagnostics and sample analysis.
The key feature is the open access nature of the instrument that allows end users to customize the instrument to target any pathogen of interest. The instrument is able to process multiple samples at a time, returning results within around one hour.
In addition to veterinary health, LexaGene is initially targeting the food safety industry to detect potential crop-killing pathogens.
--Updates share price--
Contact Angela at [email protected]
Follow her on Twitter @AHarmantas